JPRN-jRCT2080221411未知1 期
ONO-6950 Phase I Study (Single-dose, oral administration)
ONO PHARMACEUTICAL CO.,LTD.0 个研究点目标入组 56 人开始时间: 2011年3月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 35age old（—）
- 性别
- Male
入选标准
- •1. Japanese healthy adult
- •2. BMI of 18.5=< <25kg/m2
排除标准
- •1. Subject who has history or presence of clinically significant respiratory/pulmonary, cardiovascular, neurologic, psychiatric, digestive, hepatic, renal, hematopoietic, endocrine/metabolic diseases or disorders, and who is disqualified from the study at the discretion of primary investigator or sub-investigator.
研究者
相似试验
未知
1 期
ONO-6950 Phase 1 StudyAsthmaJPRN-jRCT2080221601ONO PHARMACEUTICAL CO.,LTD.52
已完成
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult SubjectsHealthy Adult SubjectsNCT01297582Ono Pharma USA Inc56
未知
1 期
A Phase 1 Study of ONO-2160/CDParkinson's diseaseJPRN-jRCT2080222143ONO PHARMACEUTICAL CO.,LTD.42
终止
1 期
Phase I dose-escalation study of oral administration of S055746 in patients with Acute Myeloid Leukaemia or Myelodysplastic SyndromeCancerISRCTN73586707Institut de Recherches Internationales Servier (France)80
尚未招募
不适用
A Phase I study to evaluate a single oral dose of SRT2379 on the endotoxin induced inflammatory response in healthy male subjectsDoor endotoxine veroorzaakte inflammatie reactieInflammationinnate immunesystem10002252NL-OMON36662Sirtris Pharmaceuticals, Inc.16